CATEGORIES: GRIN Patient Registry | Research | Research and Critical Trials
COMBINEDBRAIN HNF

CMT Biobank: We Need Your HELP!

by | Feb 1, 2024 | 0 comments

CMT Biobank: We Need Your HELP!

HNF is excited to continue collecting samples for researchers and industry to help develop treatments for CMT. CMT impacts the quality of life starting in childhood and is progressively debilitating. Currently, there are no treatments, but there are many potential therapies in the pipeline. There are still gaps in understanding the natural history of the disease correlation of genotype/ phenotype, the availability of patient biospecimens for translational research, and the validation of drug candidates and biomarkers for CMT.

HNF is the only CMT advocacy group that gives access to these patient samples at minimal cost.

The locations for specimen collection are currently being discussed. Please give us feedback if you would like us to come to a city near you!

Click here to complete the form

Learn more on this topic

Related Blog Posts

Global Registry For Inherited Neuropathies: Your Questions Answered

Global Registry For Inherited Neuropathies: Your Questions Answered

by | Nov 12, 2015 | | 0 Comments

Why are we asking you to join our registry? It’s simple. Without you, researchers won’t have the essential patient information to develop the drugs, gene therapy, and clinical trials for Charcot-Marie-Tooth and other inherited neuropathies.
This is why the Hereditary Neuropathy Foundation (HNF) created the Global Registry for Inherited Neuropathies (GRIN). The registry collects the historical, clinical, and genetic information on patients diagnosed with the various forms of inherited neuropathies to help advance therapy development for these debilitating disorders. We understand there may be some hesitation joining our registry. To help mitigate any concerns, we’ve have the answers to your most common questions.

A New Mouse Model for Charcot-Marie-Tooth (CMT2)

by | May 27, 2015 | , , | 0 Comments

We were recently informed that The Jackson Laboratory (JAX, a nonprofit biomedical research institution headquartered in Bar Harbor, Maine) had taken delivery and will be distributing a newly generated CMT-related mouse model. The new model expresses mutant mitofusin 2, a mitochondrial membrane protein involved in mitochondrial fusion and regulation of vascular smooth muscle cell proliferation.

Join the conversation

Leave a Comment

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news